Biogen

BIIB | NASDAQ | 10 Obserwujący

$129.79

-2.23%

-$2.96

Obserwuj

Overview Metrics Financials

Fair Price

$284.61

Undervalued by 58.6%

Aby wyświetlić sprawiedliwą cenę akcji, musisz być członkiem Bulios Black.

Profile

Biogen Inc. (BIIB) is an American biotechnology company specializing in the research, development, and production of therapies for neurological and neurodegenerative diseases. With a portfolio of products focused on treating multiple sclerosis, Alzheimer's disease, and other neurological disorders, Biogen is one of the leading players in the neurology field. The company is known for its emphasis on scientific research and innovation, enabling it to bring groundbreaking treatment options to patients with serious health conditions. Biogen also collaborates with academic institutions and other pharmaceutical companies to expand its research and development capabilities. Biogen Inc. (BIIB) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on neurology and neurodegenerative disease research.

Feed

There are no posts to show right now.

Menu StockBot

Tracker

Upgrade

Biogen

Fair Price

Profile

Feed

Zaloguj się do Bulios

Utwórz profil Bulios

Dlaczego Bulios?